WELCOME TO THE SECOND DAY OF #ESHCML2021

 

Highlights of Day 2
Full program  

10:20-11:50 Scientific Session III: Immunology
Chair: Agnes Yong
 

---

Welcome message from the E-conference chairpersons!

 

 

---

Are you already registered?

CLICK HERE TO ACCESS THE ON-DEMAND PROGRAM!

Seats are still available, do not miss this opportunity:

CLICK HERE TO ALSO REGISTER FOR A MEET THE EXPERT SESSION!

 

---

Do not miss the opportunity to interact with our chairs and faculty:

REGISTER NOW FOR FREE

---

Take a virtual tour of the E-Conference platform!

TIMING OF THE SCIENTIFIC PROGRAM:

Participants will be joining us from all over the world and from different time zones.To make sure that everyone has access to the full scientific program at a convenient hour,registration will allow participants to join both the LIVE PROGRAM (October 7-10, 2021)and the PROGRAM ON DEMAND (September 27 - November 10, 2021).



The “Live Program” will be streamed live CEST time.
It will include Meet the Expert sessions, interactive panel discussions, Q&A periods and Mentored Poster Walks.
It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.

The “Program on Demand” is now available.
It will initially include the pre-recorded components of the scientific program.
It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

E-POSTERS: September 27 - November 10, 2021
The Poster Hall will also remain open until November 10, 2021.
The Mentored Poster Walks scheduled in the LIVE PROGRAM will also become available in the PROGRAM ON DEMAND.

VIRTUAL EXHIBITION: September 27 - November 10, 2021
We invite you to visit the Exhibition area as of September 27.
Our corporate partners will be pleased to welcome & chat with you.

---

ABOUT THE PROGRAM:

Speakers at this meeting will present the newest and often unpublished data relating to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells, approaches to cure and treatment free remission.

The program will include:

• John Goldman Prize Lecture
• Janet Rowley Prize Lecture
• iCMLf Prize Lecture
• ESH John Goldman International Research Award presentations
• Keynote lectures
• Special lectures
• Oral communications selected from submitted abstracts
• Workshops for non-clinical scientists
• Meet-the-Expert Sessions
• Clinical and Biology manned poster walks
• Special Clinical Symposium 2021

 

---

       

---

Educational Objectives:

Upon completion of this CME activity, participants should be able to:
1. Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
2. Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
3. Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
4. Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
5. Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
6. Assess the role of allogeneic stem cell transplantation in the management of CML.
7. Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
8. Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
9. Discuss patient reported outcomes and their role in the management of patients with CML.

---

Join us on the 2021 Run.Ride.Cure challenge - Let's move towards a cure for CML

Choose between three different options to support the Run.Ride.Cure challenge:

1. Register for the challenge and raise funds

2. Get your Run.Ride.Cure charity t-shirt

3. Donate to the Run.Ride.Cure campaign  

Learn more about Run.Ride.Cure 2021 and get involved...

 

---

   

---

 

With the support of*:

        

Emerald E-Conference Partners
******

 

Ruby E-Conference Partner
******

 

*ESH conference programs are developed in strict scientific independence
with no input from corporate sponsors.